Dr. Julio Montaner, plenary speaker at the UK HIV TasP Summit in London, England

Controlling the HIV Epidemic with Antiretrovirals: From Consensus to Implementation

September 22-24, 2013
Queen Elizabeth II Conference Centre, London

The International Association of Providers of AIDS Care (IAPAC) fully embraced two biobehavioral HIV prevention interventions in 2012 – antiretroviral-based treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP) – calling for immediate integration of these interventions into the existing HIV armamentarium as a means of significantly curbing HIV incidence worldwide.

IAPAC made the announcement at the AIDS 2012 conference, where it unveiled a Consensus Statement entitled, “Controlling the HIV Epidemic with Antiretrovirals,” reflecting consensus reached by delegates of the inaugural Controlling the HIV Epidemic with Antiretrovirals evidence summit held last year in London. Click here to access the 2012 Consensus Statement.

While the concepts of TasP and PrEP have gained formidable ground since 2012, with numerous implementation and operational studies ongoing to investigate their utility, there remains much to learn about and plan for as we prepare for their integration into clinical practice. In addition, there are numerous challenges facing a variety of stakeholders as we seek to achieve the impact these biomedical prevention interventions – as part of a high impact prevention approach – promise in the third decade of the HIV pandemic.

In partnership with the British HIV Association (BHIVA), Public Health England (PHE), and Joint United Nations Programme on HIV/AIDS (UNAIDS), IAPAC will thus host its second evidence summit entitled, Controlling the HIV Epidemic with Antiretrovirals: From Consensus to Implementation, September 22-24, 2013, at the Queen Elizabeth II Conference Centre in London. The evidence summit’s goal is to provide a venue for the presentation of data related to and discussion about the implementation of TasP and PrEP in a variety of clinical settings.

An important global deliverable from this summit will be a follow-up Consensus Statement outlining key TasP and PrEP implementation recommendations. The document will be disseminated to IAPAC’s 17,000-plus clinician-members in over 100 countries, as well as through our partnerships with national, regional, and international medical and nursing associations worldwide.

For more information click HERE

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search